Prognostic impact of clinico-genetic characteristics and donor types in NPM1 -mutated AML undergoing allogeneic hematopoietic stem cell transplantation
Evaluates prognostic factors in NPM1-mutated AML patients after allogeneic hematopoietic stem cell transplantation, suggesting donor type impacts outcomes.
Key Points
This research seeks to identify prognostic factors affecting outcomes in patients with NPM1-mutated AML after transplantation.
Enrolled 139 patients with NPM1-mutated AML who underwent allogeneic HSCT.
Analyzed clinical and genetic characteristics associated with prognosis.
Conducted multivariable analysis to identify significant predictors of outcomes.
3-year cumulative incidence of relapse was 15.1%; leukemia-free survival was 78.4%; overall survival was 78.0%.
FLT3-ITD mutations linked to higher relapse rates and lower survival outcomes.
Matched sibling donor HSCT had worse outcomes compared to unrelated donors.
Pre-HSCT minimal residual disease (MRD) status was a critical predictor for outcomes.